Clinical and Experimental Rheumatology

Journal

Publication Venue For

  • Erratum corrige: "Peripheral CD4+CD28null T-cells as predictors of damage in systemic lupus erythematosus patients". M.F. Ugarte-Gil et al.  37:345. 2019
  • Peripheral CD4+CD28null T-cells as predictors of damage in systemic lupus erythematosus patients.  36:1008-1013. 2018
  • Incidence and prevalence of axial spondyloarthritis: Methodologic challenges and gaps in the literature.  36:263-274. 2018
  • Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.  35:0390-0400. 2017
  • Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis..  35:390-400. 2017
  • Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.  35:614-622. 2017
  • Fibromyalgia in 300 adult index patients with primary immunodeficiency.  35:68-73. 2017
  • Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes.  34:953. 2016
  • Fractures and mortality in relation to different osteoporosis treatments.  33:302-309. 2015
  • Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: Data from LUMINA (LXXVI), a multi-ethnic us cohort.  32:162-167. 2014
  • Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: A one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).  31:358-364. 2013
  • The safety of low-dose glucocorticoids in rheumatic diseases.  29. 2011
  • Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis.  29:582-588. 2011
  • Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis.  29. 2011
  • Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.  29:322-330. 2011
  • Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course.  29:736-742. 2011
  • Folate supplementation during Methotrexate therapy for rheumatoid arthritis.  28. 2010
  • Folate supplementation during methotrexate therapy for rheumatoid arthritis..  28:S102-S109. 2010
  • Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus form the LUMINA cohort (LXII): Use of the SF-6D.  27:64-71. 2009
  • Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): use of the SF-6D..  27:67-71. 2009
  • Mortality and osteoporotic fractures: Is the link causal, and is it modifiable?.  26. 2008
  • Mortality and osteoporotic fractures: is the link causal, and is it modifiable?.  26:S125-S137. 2008
  • Ultrasound of target joints for the evaluation of possible inflammatory arthropathy: Associated clinical factors and diagnostic accuracy.  26:875-880. 2008
  • Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: A survey of pediatric rheumatologists in the United States and Canada.  26:700-703. 2008
  • Erratum: Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI) (Clinical and Experimental Rheumatology (2008) vol. 26 (268-274)).  26:511. 2008
  • Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LUI).  26:268-274. 2008
  • Challenges in defining and improving osteoporosis quality of care.  25. 2007
  • Introduction.  25. 2007
  • Physician performance improvement: An overview of methodologies.  25. 2007
  • Challenges in defining and improving osteoporosis quality of care..  25:142-146. 2007
  • Physician performance improvement: an overview of methodologies..  25:50-54. 2007
  • Glucocorticoid use in rheumatoid arthritis: Benefits, mechanisms, and risks.  22. 2004
  • Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks..  22:S77-S82. 2004
  • Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations.  21. 2003
  • Methotrexate used as a steroid-sparing agent in non-renal chronic Henoch-Schönlein purpura.  21:767-769. 2003
  • Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations..  21:S101-S111. 2003
  • Early rheumatoid arthritis in African-Americans: The CLEAR registry.  21. 2003
  • Early rheumatoid arthritis in African-Americans: the CLEAR Registry..  21:S138-S145. 2003
  • Early rheumatoid arthritis in African-Americans: The CLEAR registry.  21:S138-S145. 2003
  • Persistent expression of a soluble form of Fas/APO1 in continuously activated T cells from a patient with SLE.  15:19-23. 1997
  • Antifolates in rheumatoid arthritis: A hypothetical mechanism of action.  11. 1993
  • Experience with a chimeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis.  11. 1993
  • The role of Fcγ receptors in mononuclear phagocyte system function.  7. 1989
  • Infection and rheumatic diseases..  7:91-97. 1989
  • Scleroderma: DR antigens, autoantibodies and clinical manifestations.  5:317-321. 1987
  • International Standard Serial Number (issn)

  • 0392-856X
  • Electronic International Standard Serial Number (eissn)

  • 1593-098X